PTC THERAPEUTICS, INC. business relationships

“| | ● | | the progress and results of activities for our votoplam program, including our right to receive any development, regulatory and sales milestones, profit sharing and royalty payments from Novartis; and |” SEC filing

“We have also relied on revenue associated with milestone and royalty payments from Roche pursuant to the SMA License Agreement under our SMA program and license revenues related to performance obligations completed pursuant to the Novartis Agreement.” SEC filing

“Business - Our Collaborations, License Agreements and Funding Arrangements - Novartis Pharmaceuticals Corporation."” SEC filing

“Pursuant to the SMA License Agreement, Roche paid us an upfront non-refundable payment of $30.0 million.” SEC filing

“While Novartis has taken over responsibility for further development of the votoplam program, we continue to collaborate with Novartis on next steps .” SEC filing

“Evrysdi is a product of our SMA program and our collaboration with Roche and the SMA Foundation.” SEC filing

“...t cash provided by operating activities for the year ended December 31, 2025, was primarily related to the upfront payment of $1.0 billion in cash received upon the closing of the Novartis Agreement in January 2025, partially offset by spend supporting clinical development and commercial activities.” SEC filing

“| | | pursuant to our Collaboration and License Agreement with a subsidiary of Ionis Pharmaceuticals, Inc., or Ionis.” SEC filing

“The retained interest sold by us to Royalty Pharma pursuant to the Amendment No. 2 is equal to 9.5111% of the Royalty before the 2020 Assigned Royalty Cap (as defined in the A&R Royalty Purchase Agreement) has been met, and 16.6666% of the Royalty from and after such time as the 2020 Assigned Royalt...” SEC filing

“As a result of the option, the Company had sold to Royalty Pharma a total of 90.49 % of the Royalty, which would have been reduced to 83.33 % (the "Assigned Royalty Rights") after Royalty Pharma receives $ 1.3 billion in aggregate payments (the "Assigned Royalty Cap") from the Royalty assigned at th...” SEC filing

“The retained interest we sold Royalty Pharma pursuant to the Amendment No. 2 is equal to 9.5111% of the Royalty before the 2020 Assigned Royalty Cap (as defined in the A&R Royalty Purchase Agreement) has been met, and 16.6666% of the Royalty from and after such time as the 2020 Assigned Royalty Cap...” SEC filing

“Amended and Restated Exclusive License and Supply Agreement, dated June 2, 2023, by and between PTC Therapeutics, Inc. and Faes Farma, S.A. (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by the Registrant on August 8, 2024)” SEC filing

“In addition, we receive royalties from PTC Therapeutics International Limited, or PTC, for TEGSEDI and WAYLIVRA sales.” SEC filing

“In 2018, we entered into an exclusive license agreement with PTC Therapeutics to commercialize TEGSEDI and WAYLIVRA in Latin America and certain Caribbean countries.” SEC filing

“One of these companies, PTC Therapeutics, Inc. and its affiliates ("PTC"), accounted for approximately 15% of our biologics and drug delivery revenues in 2025.” SEC filing

“In September 2025, the Company and PTC Therapeutics mutually agreed to terminate their existing exclusive channel collaboration ("ECC") agreement.” SEC filing

“...ucleotide candidate and a gene therapy candidate, (iv) Prilenia Therapeutics evaluating a sigma-1 receptor agonist, (v) PTC Therapeutics evaluating a splicing modifier (licensed to Novartis), (vi) Sarepta Therapeutics evaluating an siRNA, (vii) Skyhawk Therapeutics evaluating a splicing modifier, (v...” SEC filing